Plain-English translation of ·
This study is testing whether a drug called Epunamin works well when combined with a chemotherapy regimen (called DECP) for people with relapsed or refractory multiple myeloma—a blood cancer that has either returned after treatment or no longer responds to previous therapies. The goal is to see how many patients benefit from this medication combination and how safe it is in real-world clinical practice.
Multiple myeloma is a serious blood cancer that remains difficult to cure, and patients whose disease comes back or becomes resistant to standard treatments have very few options and poor outcomes. Researchers believe this new medication combination may offer hope to these patients, but they need to study it in actual patients to confirm it works.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination as part of 28-day treatment cycles, with at least 4 to 6 cycles planned if you benefit from the treatment. The first dose of Epunamin would be started at a lower level and increased gradually to help your body adjust. You would also receive blood clot prevention medication during treatment. You would need to visit the clinic regularly for blood tests, imaging, and check-ups to see how well the treatment is working and to monitor for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China